Company News

Share this article:

Endo Pharmaceuticals has partnered with Jubilant Organosys, a Bangalore-based pharma manufacturer, for the potential development of oncology preclinical candidates. Terms of the collaboration include Endo ownership and worldwide commercialization rights on any compounds developed. Under the three-year agreement, Jubilant will receive research funds from Endo, as well as success-based milestones and royalty payments should any of the compounds come to fruition.

 

Top pharma brass – John Lechleiter, CEO at Lilly and Adam Schechter, president of global pharmaceuticals at Merck – made separate statements on Wednesday opposing a government-run healthcare offering that would compete with private insurers, Reuters reported. “You'd have 100 million people shuttled in overnight; it would limit coverage and delay access,” said Lechleiter. The statements were made at the Goldman Sachs Annual Healthcare Conference in New York.

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.